🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

RecruitingNAAges 18 Years - 75 YearsAllInstitute of Liver and Biliary Sciences, India
NCT01212250 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients of cirrhosis aged 18 to 75 years who have no esophageal or gastric varices. Exclusion Criteria: * Any contra-indication to beta-blockers * Any past EVL or sclerotherapy * Any past history of surgery for portal hypertension * Significant cardio or pulmonary co-morbidity * Any malignancy * Refusal to participate in the study
💊

What it tests

  • carvedilol
  • Placebo
📍

Where

1 site
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, India
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy